A1166C polymorphism of the angiotensin II type 1 receptor gene and risk ofadverse events after coronary catheter interventions

Background Contradictory reports exist concerning the role of the angiotens in II type 1 receptor A1166C polymorphism as a coronary risk factor. Moreov er, it is unknown whether the A1166C polymorphism is associated with thromb otic complications after coronary catheter interventions. Methods We investigated the role of the A1166C polymorphism as a risk facto r in 1000 patients with coronary artery disease (CAD) and in 1000 age- and sex-matched controls. A total of 649 patients receiving interventions (270 coronary angioplasty, 102 atherectomy, and 277 stenting) were investigated for a 30-day composite end point including target vessel revascularization, myocardial infarction, or death. Results The composite end point was reached by 42 patients (6.5%) without e vidence that the C allele was associated with excess procedural risk (odds ratio 0.93; 95% confidence interval 0.79-1.75; P = .82). Further analyses b y device failed to show linkage with adverse events complicating coronary a ngioplasty, atherectomy, and stenting. Moreover, in the entire CAD group (n = 1000), the polymorphism even showed a trend to underrepresentation (odds ratio 0.83; 95% confidence interval 0.69-1.004 P = .054). Conclusions These results indicate that the A1166C polymorphism neither rep resents a risk Factor for adverse events complicating coronary intervention s nor seems to have significant impact on further long-term processes such as development and severity of CAD.